Journal
CELL STEM CELL
Volume 23, Issue 2, Pages 181-+Publisher
CELL PRESS
DOI: 10.1016/j.stem.2018.06.002
Keywords
-
Categories
Funding
- NIH [R01CA203348, U01 CA217885]
- CIRM [DISC2-09615]
- Fate Therapeutics
- NATIONAL CANCER INSTITUTE [R01CA203348, U01CA217885, T32CA009138] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Chimeric antigen receptors (CARs) significantly enhance the anti-tumor activity of immune effector cells. Although most studies have evaluated CAR expression in T cells, here we evaluate different CAR constructs that improve natural killer (NK) cell-mediated killing. We identified a CAR containing the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3 zeta signaling domain to mediate strong antigen-specific NK cell signaling. NK cells derived from human iPSCs that express this CAR (NK-CAR-iPSC-NK cells) have a typical NK cell phenotype and demonstrate improved antitumor activity compared with T-CAR-expressing iPSC-derived NK cells (T-CAR-iPSC-NK cells) and non-CAR-expressing cells. In an ovarian cancer xenograft model, NK-CAR-iPSC-NK cells significantly inhibited tumor growth and prolonged survival compared with PB-NK cells, iPSC-NK cells, or T-CAR-iPSC-NK cells. Additionally, NK-CAR-iPSC-NK cells demonstrate in vivo activity similar to that of T-CAR-expressing T cells, although with less toxicity. These NK-CAR-iPSC-NK cells now provide standardized, targeted off-the-shelf lymphocytes for anti-cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available